[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Medroxyprogesterone acetate.]
[G03XB02, ulipristal, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Streptokinase.]
[J01GA01, streptomycin, Medroxyprogesterone acetate may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CG01, sulbactam, Medroxyprogesterone acetate may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Medroxyprogesterone acetate.]
[M04AB02, sulfinpyrazone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Medroxyprogesterone acetate.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AX03, sulthiame, The metabolism of Medroxyprogesterone acetate can be increased when combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Medroxyprogesterone acetate.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CA15, talampicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Talampicillin.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be decreased when it is combined with Medroxyprogesterone acetate.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Medroxyprogesterone acetate.]
[R03CC03, terbutaline, Medroxyprogesterone acetate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Tetracaine.]
[S03AA02, tetracycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Medroxyprogesterone acetate.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Medroxyprogesterone acetate.]
[L04AX02, thalidomide, Medroxyprogesterone acetate may increase the thrombogenic activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Medroxyprogesterone acetate may decrease the excretion rate of Theophylline which could result in a higher serum level.]
[P02CA02, thiabendazole, Medroxyprogesterone acetate may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Medroxyprogesterone acetate.]
[N05CA19, thiopental, The metabolism of Medroxyprogesterone acetate can be increased when combined with Thiopental.]
[G04BE06, moxisylyte, Medroxyprogesterone acetate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Medroxyprogesterone acetate may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[J01CA13, ticarcillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ticarcillin.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[P01AB02, tinidazole, Medroxyprogesterone acetate may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Medroxyprogesterone acetate may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Medroxyprogesterone acetate.]
[B02AA02, tranexamic acid, Medroxyprogesterone acetate may increase the thrombogenic activities of Tranexamic acid.]
[L01XF01, tretinoin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tretinoin.]
[S01BA05, triamcinolone, The serum concentration of Triamcinolone can be increased when it is combined with Medroxyprogesterone acetate.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Medroxyprogesterone acetate may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Medroxyprogesterone acetate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Trifluridine.]
[D07AC02, fluclorolone, The serum concentration of Fluclorolone can be increased when it is combined with Medroxyprogesterone acetate.]
[R03BA07, mometasone, The serum concentration of Mometasone can be increased when it is combined with Medroxyprogesterone acetate.]
[A03AA05, trimebutine, Medroxyprogesterone acetate may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AC02, trimethadione, The metabolism of Medroxyprogesterone acetate can be increased when combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Medroxyprogesterone acetate.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Medroxyprogesterone acetate.]
[J01FA08, troleandomycin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Medroxyprogesterone acetate.]
[L01FX04, ipilimumab, Medroxyprogesterone acetate may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Medroxyprogesterone acetate.]
[R02AA14, oxyquinoline, Medroxyprogesterone acetate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.]
[J05AP03, boceprevir, The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Medroxyprogesterone acetate.]
[B01AD04, urokinase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Urokinase.]
[S01AA28, vancomycin, Medroxyprogesterone acetate may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Medroxyprogesterone acetate.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Medroxyprogesterone acetate.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Medroxyprogesterone acetate.]
[S01XA02, vitamin A, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Vitamin A.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A11HA03, vitamin E, The metabolism of Medroxyprogesterone acetate can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Medroxyprogesterone acetate.]
[S01AA13, fusidic acid, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Medroxyprogesterone acetate.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Medroxyprogesterone acetate.]
[J05AE02, indinavir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Medroxyprogesterone acetate.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Medroxyprogesterone acetate.]
[M05BA05, tiludronic acid, Medroxyprogesterone acetate may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Medroxyprogesterone acetate may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Medroxyprogesterone acetate.]
[B01AE01, desirudin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Medroxyprogesterone acetate.]
[A02BC04, rabeprazole, Medroxyprogesterone acetate may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Medroxyprogesterone acetate may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Medroxyprogesterone acetate.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Medroxyprogesterone acetate.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Medroxyprogesterone acetate.]
[J01DH04, doripenem, Medroxyprogesterone acetate may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Medroxyprogesterone acetate may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Medroxyprogesterone acetate.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Medroxyprogesterone acetate.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Medroxyprogesterone acetate.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Medroxyprogesterone acetate.]
[L01BC07, azacitidine, Medroxyprogesterone acetate may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Medroxyprogesterone acetate may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CA09, azlocillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Azlocillin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Medroxyprogesterone acetate.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A08AA11, lorcaserin, Medroxyprogesterone acetate may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Medroxyprogesterone acetate may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[V03AX03, cobicistat, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Medroxyprogesterone acetate.]
[B01AX01, defibrotide, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Defibrotide.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Medroxyprogesterone acetate.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Medroxyprogesterone acetate.]
[N05CA04, barbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Barbital.]
[D02BA02, octinoxate, Medroxyprogesterone acetate may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Medroxyprogesterone acetate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Medroxyprogesterone acetate.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Medroxyprogesterone acetate.]
[V09IX04, fluorodeoxyglucose F18, Medroxyprogesterone acetate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Medroxyprogesterone acetate.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Medroxyprogesterone acetate.]
[V08CA11, gadofosveset, Medroxyprogesterone acetate may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Medroxyprogesterone acetate.]
[B01AF02, apixaban, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Apixaban.]
[A16AX08, teduglutide, Medroxyprogesterone acetate may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Medroxyprogesterone acetate.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone acetate.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Medroxyprogesterone acetate can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Medroxyprogesterone acetate.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Medroxyprogesterone acetate.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Medroxyprogesterone acetate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Medroxyprogesterone acetate.]
[L03AA12, ancestim, Medroxyprogesterone acetate may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Medroxyprogesterone acetate.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Medroxyprogesterone acetate.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EE01, trametinib, Medroxyprogesterone acetate may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Medroxyprogesterone acetate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Medroxyprogesterone acetate.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Medroxyprogesterone acetate.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Medroxyprogesterone acetate.]
[A05AA03, cholic acid, The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Medroxyprogesterone acetate.]
[C02KX04, macitentan, Medroxyprogesterone acetate may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Medroxyprogesterone acetate.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Medroxyprogesterone acetate.]
[N03AF04, eslicarbazepine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Medroxyprogesterone acetate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.]
[C01CA27, droxidopa, Medroxyprogesterone acetate may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Medroxyprogesterone acetate.]
[A16AA07, metreleptin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Medroxyprogesterone acetate may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, The metabolism of Medroxyprogesterone acetate can be increased when combined with Formestane.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Medroxyprogesterone acetate.]
[B01AE03, argatroban, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Argatroban.]
[V03AB34, fomepizole, Medroxyprogesterone acetate may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Medroxyprogesterone acetate.]
[L04AC11, siltuximab, The metabolism of Medroxyprogesterone acetate can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Medroxyprogesterone acetate.]
[B01AC26, vorapaxar, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Medroxyprogesterone acetate.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Medroxyprogesterone acetate.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Medroxyprogesterone acetate.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Medroxyprogesterone acetate.]
[J01XA05, oritavancin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Medroxyprogesterone acetate.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Medroxyprogesterone acetate.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Medroxyprogesterone acetate.]
[S03AA06, gentamicin, Medroxyprogesterone acetate may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Medroxyprogesterone acetate.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Medroxyprogesterone acetate.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Edoxaban.]
[B06AC01, C1 esterase inhibitor (human), The risk or severity of thromboembolism can be increased when Medroxyprogesterone acetate is combined with Human C1-esterase inhibitor.]
[B06AC04, C1 esterase inhibitor (recombinant), The risk or severity of thromboembolism can be increased when Medroxyprogesterone acetate is combined with Conestat alfa.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Medroxyprogesterone acetate.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Medroxyprogesterone acetate.]
[N02BE01, acetaminophen, The metabolism of Medroxyprogesterone acetate can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Medroxyprogesterone acetate.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Flibanserin.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Medroxyprogesterone acetate.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01EC01, acetazolamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Medroxyprogesterone acetate.]
[D05BB02, acitretin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Acitretin.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Medroxyprogesterone acetate.]
[V03AB37, idarucizumab, Medroxyprogesterone acetate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Medroxyprogesterone acetate.]
[J02AC05, isavuconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Medroxyprogesterone acetate.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Medroxyprogesterone acetate.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Medroxyprogesterone acetate.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Medroxyprogesterone acetate.]
[V03AB35, sugammadex, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sugammadex.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Medroxyprogesterone acetate.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Medroxyprogesterone acetate.]
[M04AB05, lesinurad, The metabolism of Medroxyprogesterone acetate can be increased when combined with Lesinurad.]
[N05CA05, aprobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AX23, brivaracetam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Medroxyprogesterone acetate.]
[N05BA08, bromazepam, Medroxyprogesterone acetate may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Medroxyprogesterone acetate.]
[A02AD05, aluminum magnesium silicate, Medroxyprogesterone acetate may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Medroxyprogesterone acetate.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Medroxyprogesterone acetate.]
[A05AA04, obeticholic acid, The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Medroxyprogesterone acetate.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Bupivacaine.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Medroxyprogesterone acetate.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Medroxyprogesterone acetate.]
[L01XX27, arsenic trioxide, Medroxyprogesterone acetate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Medroxyprogesterone acetate.]
[M02AA03, clofezone, Medroxyprogesterone acetate may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Medroxyprogesterone acetate.]
[J01CE04, azidocillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Azidocillin.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Medroxyprogesterone acetate.]
[J01CA06, bacampicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Bacampicillin.]
[L01EF02, ribociclib, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A06AH05, naldemedine, Medroxyprogesterone acetate may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Medroxyprogesterone acetate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Pregabalin.]
[N03AX30, beclamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Beclamide.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Medroxyprogesterone acetate.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Medroxyprogesterone acetate can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Medroxyprogesterone acetate may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Medroxyprogesterone acetate may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Medroxyprogesterone acetate may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Medroxyprogesterone acetate.]
[L04AC14, sarilumab, The metabolism of Medroxyprogesterone acetate can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Medroxyprogesterone acetate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Betrixaban.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Medroxyprogesterone acetate.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Medroxyprogesterone acetate.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Medroxyprogesterone acetate.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Medroxyprogesterone acetate.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.]
[C07AB07, bisoprolol, Medroxyprogesterone acetate may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J05AG03, efavirenz, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Medroxyprogesterone acetate.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Medroxyprogesterone acetate.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Medroxyprogesterone acetate.]
[R06AX18, acrivastine, Medroxyprogesterone acetate may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Carbamazepine.]
[J01CA03, carbenicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Carbenicillin.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Medroxyprogesterone acetate.]
[N03AX24, cannabidiol, The metabolism of Medroxyprogesterone acetate can be increased when combined with Cannabidiol.]
[L04AA37, baricitinib, Medroxyprogesterone acetate may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01GB14, plazomicin, Medroxyprogesterone acetate may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Medroxyprogesterone acetate.]
[L01XX62, ivosidenib, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Medroxyprogesterone acetate may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Medroxyprogesterone acetate can be increased when combined with Tecovirimat.]
[J01AA13, eravacycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Eravacycline.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Medroxyprogesterone acetate.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Medroxyprogesterone acetate.]
[J01AA14, sarecycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Omadacycline.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Medroxyprogesterone acetate.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Medroxyprogesterone acetate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Medroxyprogesterone acetate.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Medroxyprogesterone acetate can be increased when combined with Lorlatinib.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Medroxyprogesterone acetate.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Medroxyprogesterone acetate.]
[A06AX05, prucalopride, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Prucalopride.]
[B01AC23, cilostazol, Medroxyprogesterone acetate may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Medroxyprogesterone acetate.]
[N06AX27, esketamine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Medroxyprogesterone acetate.]
[J01FA09, clarithromycin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Medroxyprogesterone acetate may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N06AX29, brexanolone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Medroxyprogesterone acetate.]
[N05BA09, clobazam, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Clobazam.]
[J01AA11, clomocycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Clomocycline.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Medroxyprogesterone acetate.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Medroxyprogesterone acetate.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Medroxyprogesterone acetate.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CF03, methicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Meticillin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Medroxyprogesterone acetate.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Medroxyprogesterone acetate.]
[N07XX11, pitolisant, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Medroxyprogesterone acetate.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Medroxyprogesterone acetate.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Medroxyprogesterone acetate.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Medroxyprogesterone acetate.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DB09, cephradine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Medroxyprogesterone acetate.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Medroxyprogesterone acetate.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Medroxyprogesterone acetate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Medroxyprogesterone acetate.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Medroxyprogesterone acetate.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Medroxyprogesterone acetate.]
[N03AX25, cenobamate, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M09AX08, golodirsen, Medroxyprogesterone acetate may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Medroxyprogesterone acetate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Medroxyprogesterone acetate.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Medroxyprogesterone acetate.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Medroxyprogesterone acetate.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Medroxyprogesterone acetate.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Medroxyprogesterone acetate.]
[J05AE05, amprenavir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Medroxyprogesterone acetate.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Medroxyprogesterone acetate.]
[R02AA03, dichlorobenzyl alcohol, Medroxyprogesterone acetate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Medroxyprogesterone acetate.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Medroxyprogesterone acetate.]
[M01AH02, rofecoxib, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Medroxyprogesterone acetate.]
[N03AG02, dipropylacetamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Valpromide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Medroxyprogesterone acetate.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Medroxyprogesterone acetate.]
[D07XB03, fluprednidene, The serum concentration of Fluprednidene can be increased when it is combined with Medroxyprogesterone acetate.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[V08CA05, mangafodipir, Medroxyprogesterone acetate may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Medroxyprogesterone acetate.]
[B01AE02, lepirudin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Lepirudin.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05CM02, chlormethiazole, The metabolism of Medroxyprogesterone acetate can be increased when combined with Clomethiazole.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Dyclonine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Medroxyprogesterone acetate.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Medroxyprogesterone acetate.]
[L04AC19, satralizumab, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Medroxyprogesterone acetate.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Medroxyprogesterone acetate.]
[L01EX23, pralsetinib, The metabolism of Medroxyprogesterone acetate can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Medroxyprogesterone acetate may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Vinpocetine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Medroxyprogesterone acetate.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Medroxyprogesterone acetate.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[B06AC06, berotralstat, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Medroxyprogesterone acetate.]
[M01AX25, chondroitin sulfates, Medroxyprogesterone acetate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The metabolism of Medroxyprogesterone acetate can be increased when combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01CA19, fenoldopam, Medroxyprogesterone acetate may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Medroxyprogesterone acetate.]
[S02BA08, fluocinolone acetonide, The serum concentration of Fluocinolone acetonide can be increased when it is combined with Medroxyprogesterone acetate.]
[N02BG07, flupirtine, Medroxyprogesterone acetate may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Medroxyprogesterone acetate.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Medroxyprogesterone acetate.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Medroxyprogesterone acetate.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02BF01, gabapentin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Gabapentin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Medroxyprogesterone acetate.]
[L01XX73, sotorasib, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Medroxyprogesterone acetate.]
[S03AA07, ciprofloxacin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Medroxyprogesterone acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Medroxyprogesterone acetate.]
[L01XX74, belzutifan, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Medroxyprogesterone acetate may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Medroxyprogesterone acetate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Medroxyprogesterone acetate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Medroxyprogesterone acetate.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Medroxyprogesterone acetate.]
[N06AX25, St. John's wort extract, The metabolism of Medroxyprogesterone acetate can be increased when combined with St. John's Wort.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Medroxyprogesterone acetate.]
[B01AD11, tenecteplase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Medroxyprogesterone acetate can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Medroxyprogesterone acetate can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Medroxyprogesterone acetate.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Medroxyprogesterone acetate.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Medroxyprogesterone acetate is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A10BX16, tirzepatide, Tirzepatide can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Medroxyprogesterone acetate.]
[J01CF02, cloxacillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Cloxacillin.]
[N05AH02, clozapine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01GB12, arbekacin, Medroxyprogesterone acetate may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Medroxyprogesterone acetate can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Cocaine.]
[M09AX11, palovarotene, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Palovarotene.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CA18, hetacillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Hetacillin.]
[M04AC01, colchicine, Medroxyprogesterone acetate may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, Medroxyprogesterone acetate may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Medroxyprogesterone acetate.]
[A04AA03, tropisetron, Medroxyprogesterone acetate may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Medroxyprogesterone acetate.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01FA15, telithromycin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Medroxyprogesterone acetate.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J05AB14, valganciclovir, Medroxyprogesterone acetate may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Medroxyprogesterone acetate may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Medroxyprogesterone acetate may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Medroxyprogesterone acetate may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Medroxyprogesterone acetate may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Medroxyprogesterone acetate may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Medroxyprogesterone acetate.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Medroxyprogesterone acetate.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Medroxyprogesterone acetate.]
[J02AC02, itraconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05BA10, ketazolam, Medroxyprogesterone acetate may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Medroxyprogesterone acetate.]
[J02AC04, posaconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Medroxyprogesterone acetate.]
[N03AX09, lamotrigine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The serum concentration of Cortisone can be increased when it is combined with Medroxyprogesterone acetate.]
[N07BC04, lofexidine, Medroxyprogesterone acetate may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C09AA03, lisinopril, Medroxyprogesterone acetate may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Medroxyprogesterone acetate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Medroxyprogesterone acetate.]
[J01DH02, meropenem, Medroxyprogesterone acetate may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[J01CA14, methampicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Metampicillin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Medroxyprogesterone acetate may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Medroxyprogesterone acetate.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Medroxyprogesterone acetate.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Medroxyprogesterone acetate.]
[N06BA07, modafinil, The metabolism of Medroxyprogesterone acetate can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, Rosuvastatin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Medroxyprogesterone acetate.]
[L01AX04, dacarbazine, Medroxyprogesterone acetate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Medroxyprogesterone acetate.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Medroxyprogesterone acetate.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Medroxyprogesterone acetate.]
[N07BB05, nalmefene, Medroxyprogesterone acetate may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[J01AA01, demeclocycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Demeclocycline.]
[S01GX04, nedocromil, Medroxyprogesterone acetate may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Medroxyprogesterone acetate may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Medroxyprogesterone acetate may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Tiagabine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Medroxyprogesterone acetate.]
[B01AX05, fondaparinux, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Fondaparinux.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N06AA01, desipramine, Medroxyprogesterone acetate may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[D07XC02, desoximetasone, The serum concentration of Desoximetasone can be increased when it is combined with Medroxyprogesterone acetate.]
[V04CH02, indigo carmine, Medroxyprogesterone acetate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The serum concentration of Desoxycortone can be increased when it is combined with Medroxyprogesterone acetate.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Medroxyprogesterone acetate.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Medroxyprogesterone acetate.]
[N03AC01, paramethadione, The metabolism of Medroxyprogesterone acetate can be increased when combined with Paramethadione.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Medroxyprogesterone acetate.]
[C01DA05, pentaerythritol tetranitrate, Medroxyprogesterone acetate may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Medroxyprogesterone acetate may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Diazepam.]
[N03AX07, phenacemide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenacemide.]
[J01CE05, phenethicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Phenol.]
[N03AD02, phensuximide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Phensuximide.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Cinchocaine.]
[R05DA08, pholcodine, Medroxyprogesterone acetate may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Medroxyprogesterone acetate.]
[J01CF01, dicloxacillin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A03AA07, dicyclomine, Medroxyprogesterone acetate may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Medroxyprogesterone acetate may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Medroxyprogesterone acetate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Medroxyprogesterone acetate.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Medroxyprogesterone acetate.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Medroxyprogesterone acetate.]
[C08CA03, isradipine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The serum concentration of Difluocortolone can be increased when it is combined with Medroxyprogesterone acetate.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Medroxyprogesterone acetate.]
[C01AA05, digoxin, Medroxyprogesterone acetate may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Medroxyprogesterone acetate.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Medroxyprogesterone acetate.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Medroxyprogesterone acetate.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J05AE08, atazanavir, The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Medroxyprogesterone acetate.]
[H03BC01, potassium perchlorate, Medroxyprogesterone acetate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Medroxyprogesterone acetate may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Medroxyprogesterone acetate may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Medroxyprogesterone acetate may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Progabide.]
[J01CE03, propicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Propicillin.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Medroxyprogesterone acetate.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Medroxyprogesterone acetate.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Medroxyprogesterone acetate.]
[S01AX06, resorcinol, Medroxyprogesterone acetate may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Medroxyprogesterone acetate.]
[S02AA12, rifamycin SV, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Medroxyprogesterone acetate can be increased when combined with Riluzole.]
[R06AE09, levocetirizine, Medroxyprogesterone acetate may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Medroxyprogesterone acetate.]
[A04AD12, aprepitant, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Medroxyprogesterone acetate.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Medroxyprogesterone acetate.]
[G04BE08, tadalafil, Medroxyprogesterone acetate may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Medroxyprogesterone acetate.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Medroxyprogesterone acetate.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01CA07, dobutamine, Medroxyprogesterone acetate may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Medroxyprogesterone acetate.]
[C01CA04, dopamine, Medroxyprogesterone acetate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Medroxyprogesterone acetate.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Medroxyprogesterone acetate.]
[J01AA02, doxycycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Doxycycline.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Medroxyprogesterone acetate.]
[A08AA10, sibutramine, Medroxyprogesterone acetate may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Medroxyprogesterone acetate.]
[A12CA02, sodium sulfate, Medroxyprogesterone acetate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Medroxyprogesterone acetate may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Medroxyprogesterone acetate may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Medroxyprogesterone acetate may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Medroxyprogesterone acetate.]
[J01CA17, temocillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Temocillin.]
[L01AX03, temozolomide, Medroxyprogesterone acetate may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Medroxyprogesterone acetate.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Medroxyprogesterone acetate.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Medroxyprogesterone acetate.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N06AG03, toloxatone, Medroxyprogesterone acetate may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AX11, topiramate, The metabolism of Medroxyprogesterone acetate can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Medroxyprogesterone acetate.]
[J01AA12, tigecycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tigecycline.]
[N05CC01, chloral hydrate, Medroxyprogesterone acetate may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Triflusal.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Medroxyprogesterone acetate.]
[C05CA04, troxerutin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Troxerutin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Medroxyprogesterone acetate.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C08CA12, mepirodipine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Medroxyprogesterone acetate.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AX15, zonisamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Medroxyprogesterone acetate.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Medroxyprogesterone acetate.]
[B01AD03, anistreplase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C02AC02, guanfacine, Medroxyprogesterone acetate may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02CA02, ergotamine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Medroxyprogesterone acetate can be increased when combined with Valproic acid.]
[L03AX05, pidotimod, Medroxyprogesterone acetate may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The serum concentration of Fluticasone furoate can be increased when it is combined with Medroxyprogesterone acetate.]
[R03BA05, fluticasone, The serum concentration of Fluticasone can be increased when it is combined with Medroxyprogesterone acetate.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Medroxyprogesterone acetate.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Medroxyprogesterone acetate.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N03AD01, ethosuximide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ethosuximide.]
[N03AB01, ethotoin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Medroxyprogesterone acetate.]
[D05BB01, etretinate, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Etretinate.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Medroxyprogesterone acetate.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Medroxyprogesterone acetate.]
[R06AX12, terfenadine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Medroxyprogesterone acetate may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Medroxyprogesterone acetate.]
[N06AB08, fluvoxamine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Medroxyprogesterone acetate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Medroxyprogesterone acetate.]
[D11AX24, deoxycholic acid, The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Medroxyprogesterone acetate.]
[B05AA05, dextran, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Medroxyprogesterone acetate.]
[N03AX26, fenfluramine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02AB03, fentanyl, Medroxyprogesterone acetate may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Medroxyprogesterone acetate may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Fibrinolysin.]
[L01BB06, clofarabine, Medroxyprogesterone acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[G04BD02, flavoxate, Medroxyprogesterone acetate may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CF05, floxacillin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The bioavailability of Medroxyprogesterone acetate can be increased when combined with Fluconazole.]
[J02AX01, flucytosine, Medroxyprogesterone acetate may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Medroxyprogesterone acetate.]
[V03AB25, flumazenil, Medroxyprogesterone acetate may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The serum concentration of Flumethasone can be increased when it is combined with Medroxyprogesterone acetate.]
[N07CA03, flunarizine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Medroxyprogesterone acetate.]
[D07AC08, fluocinonide, The serum concentration of Fluocinonide can be increased when it is combined with Medroxyprogesterone acetate.]
[H02AB03, fluocortolone, The serum concentration of Fluocortolone can be increased when it is combined with Medroxyprogesterone acetate.]
[V03AZ01, ethanol, The metabolism of Medroxyprogesterone acetate can be increased when combined with Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01CB05, fluorometholone, The serum concentration of Fluorometholone can be increased when it is combined with Medroxyprogesterone acetate.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Medroxyprogesterone acetate.]
[N06AB03, fluoxetine, The metabolism of Fluoxetine can be decreased when combined with Medroxyprogesterone acetate.]
[N05CD01, flurazepam, Medroxyprogesterone acetate may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Medroxyprogesterone acetate.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S02AA17, fosfomycin, Medroxyprogesterone acetate may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Medroxyprogesterone acetate.]
[J05AE10, darunavir, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Medroxyprogesterone acetate.]
[S01AD09, ganciclovir, Medroxyprogesterone acetate may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, Medroxyprogesterone acetate may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Medroxyprogesterone acetate may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Medroxyprogesterone acetate.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Medroxyprogesterone acetate.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Medroxyprogesterone acetate.]
[J05AG04, etravirine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Medroxyprogesterone acetate.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Medroxyprogesterone acetate.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Medroxyprogesterone acetate.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.]
[N05CM18, dexmedetomidine, Medroxyprogesterone acetate may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Medroxyprogesterone acetate.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Medroxyprogesterone acetate.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Medroxyprogesterone acetate.]
[M01CB04, aurothioglucose, Medroxyprogesterone acetate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Medroxyprogesterone acetate may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[D01BA01, griseofulvin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Medroxyprogesterone acetate may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Medroxyprogesterone acetate.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Medroxyprogesterone acetate.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Medroxyprogesterone acetate.]
[N05AH04, quetiapine, Medroxyprogesterone acetate may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Medroxyprogesterone acetate may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Medroxyprogesterone acetate.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Medroxyprogesterone acetate.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Medroxyprogesterone acetate.]
[S01XA14, heparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Medroxyprogesterone acetate.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05CA16, hexobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Medroxyprogesterone acetate.]
[C08CA10, nilvadipine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C09AA04, perindopril, Medroxyprogesterone acetate may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Medroxyprogesterone acetate may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Medroxyprogesterone acetate.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Hydrocortisone butyrate can be increased when it is combined with Medroxyprogesterone acetate.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Medroxyprogesterone acetate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[G04BD06, propiverine, Medroxyprogesterone acetate may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Medroxyprogesterone acetate.]
[B05AA07, hetastarch, Medroxyprogesterone acetate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[J04AB04, rifabutin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Medroxyprogesterone acetate.]
[B05XA08, sodium acetate, Medroxyprogesterone acetate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Medroxyprogesterone acetate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Medroxyprogesterone acetate.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Medroxyprogesterone acetate.]
[R01AD07, tixocortol, The serum concentration of Tixocortol can be increased when it is combined with Medroxyprogesterone acetate.]
[M03BX02, tizanidine, The metabolism of Medroxyprogesterone acetate can be increased when combined with Tizanidine.]
[L01CE01, topotecan, Medroxyprogesterone acetate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be decreased when combined with Medroxyprogesterone acetate.]
[A11HA07, inositol, Medroxyprogesterone acetate may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Medroxyprogesterone acetate.]
[S01XA28, varenicline, Medroxyprogesterone acetate may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Medroxyprogesterone acetate.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Medroxyprogesterone acetate.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Medroxyprogesterone acetate.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Medroxyprogesterone acetate may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J04AC01, isoniazid, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Medroxyprogesterone acetate may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, Exenatide can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01DA14, isosorbide mononitrate, Medroxyprogesterone acetate may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin.]
[B01AE06, bivalirudin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Bivalirudin.]
[S01AA24, kanamycin, Medroxyprogesterone acetate may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Medroxyprogesterone acetate can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Medroxyprogesterone acetate.]
[B01AC22, prasugrel, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[V03AC03, deferasirox, The metabolism of Medroxyprogesterone acetate can be increased when combined with Deferasirox.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N04BB01, amantadine, Medroxyprogesterone acetate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Medroxyprogesterone acetate may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA02, ursodiol, The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01CA11, amdinocillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Pivmecillinam.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Medroxyprogesterone acetate.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Lidocaine.]
[S01AA21, amikacin, Medroxyprogesterone acetate may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Medroxyprogesterone acetate can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Medroxyprogesterone acetate.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Medroxyprogesterone acetate.]
[N05BA06, lorazepam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lymecycline.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Medroxyprogesterone acetate.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Medroxyprogesterone acetate.]
[B05XA11, magnesium chloride, Medroxyprogesterone acetate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Medroxyprogesterone acetate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The metabolism of Medroxyprogesterone acetate can be increased when combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Medroxyprogesterone acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Medroxyprogesterone acetate may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Medroxyprogesterone acetate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05BA03, medazepam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Medazepam.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dalteparin.]
[N06DX01, memantine, Medroxyprogesterone acetate may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Medroxyprogesterone acetate.]
[N03AB04, mephenytoin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Mepivacaine.]
[G04BX16, tiopronin, Medroxyprogesterone acetate may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Medroxyprogesterone acetate may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.]
[J01AA05, methacycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Metacycline.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Medroxyprogesterone acetate.]
[N06BA03, methamphetamine, Medroxyprogesterone acetate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Medroxyprogesterone acetate may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Metharbital.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Medroxyprogesterone acetate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Medroxyprogesterone acetate.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Medroxyprogesterone acetate.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Medroxyprogesterone acetate may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Medroxyprogesterone acetate may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Medroxyprogesterone acetate.]
[D07AC14, methylprednisolone aceponate, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Medroxyprogesterone acetate.]
[N03AF03, rufinamide, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Medroxyprogesterone acetate may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Medroxyprogesterone acetate.]
[A03FA01, metoclopramide, Medroxyprogesterone acetate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[V04CD01, metyrapone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Metyrapone.]
[J01CA10, mezlocillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Mezlocillin.]
[S02AA13, miconazole, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Medroxyprogesterone acetate.]
[B01AB07, parnaparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Parnaparin.]
[N05CD08, midazolam, Medroxyprogesterone acetate may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Medroxyprogesterone acetate.]
[B01AB10, tinzaparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Medroxyprogesterone acetate.]
[J01AA08, minocycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Minocycline.]
[L01XX23, mitotane, The metabolism of Medroxyprogesterone acetate can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Medroxyprogesterone acetate.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Medroxyprogesterone acetate.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Medroxyprogesterone acetate may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Medroxyprogesterone acetate.]
[G04BA01, ammonium chloride, Medroxyprogesterone acetate may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Medroxyprogesterone acetate.]
[L04AA06, mycophenolic acid, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Medroxyprogesterone acetate.]
[N03AB05, fosphenytoin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Medroxyprogesterone acetate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Amoxicillin.]
[J01CF06, nafcillin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Naloxone.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Medroxyprogesterone acetate.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Medroxyprogesterone acetate.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Medroxyprogesterone acetate.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Medroxyprogesterone acetate.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Medroxyprogesterone acetate.]
[S03AA01, neomycin, Medroxyprogesterone acetate may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Medroxyprogesterone acetate.]
[B01AC17, tirofiban, Medroxyprogesterone acetate may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01AA19, ampicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ampicillin.]
[L03AX16, plerixafor, Medroxyprogesterone acetate may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Medroxyprogesterone acetate may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01CE01, inamrinone, Medroxyprogesterone acetate may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C08CA04, nicardipine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Medroxyprogesterone acetate.]
[C08CA05, nifedipine, Medroxyprogesterone acetate may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05CD02, nitrazepam, The metabolism of Medroxyprogesterone acetate can be increased when combined with Nitrazepam.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Medroxyprogesterone acetate may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Medroxyprogesterone acetate can be increased when combined with Zaleplon.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Medroxyprogesterone acetate.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Medroxyprogesterone acetate.]
[C02KX01, bosentan, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Medroxyprogesterone acetate.]
[B01AB08, reviparin, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Octreotide.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Medroxyprogesterone acetate.]
[N02AA02, opium, Medroxyprogesterone acetate may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Ancrod.]
[G04CA02, tamsulosin, Medroxyprogesterone acetate may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Oxacillin.]
[N05BA04, oxazepam, Medroxyprogesterone acetate may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01AA04, oxytetracycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Oxytetracycline.]
[B01AB09, danaparoid, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Danaparoid.]
[J04AB30, capreomycin, Medroxyprogesterone acetate may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Medroxyprogesterone acetate.]
[N05CC05, paraldehyde, The metabolism of Medroxyprogesterone acetate can be increased when combined with Paraldehyde.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Medroxyprogesterone acetate.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[G04BD11, fesoterodine, Medroxyprogesterone acetate may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Medroxyprogesterone acetate may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[S01AA14, penicillin G, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Medroxyprogesterone acetate may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Medroxyprogesterone acetate may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Medroxyprogesterone acetate.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N06AF03, phenelzine, Medroxyprogesterone acetate may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Medroxyprogesterone acetate.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Phenprocoumon.]
[V03AB36, phentolamine, Medroxyprogesterone acetate may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenytoin.]
[L01XF02, alitretinoin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Alitretinoin.]
[S01AE05, levofloxacin, Medroxyprogesterone acetate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Medroxyprogesterone acetate.]
[B02BA01, vitamin K1, Medroxyprogesterone acetate may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Medroxyprogesterone acetate.]
[C07AA03, pindolol, Medroxyprogesterone acetate may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Medroxyprogesterone acetate.]
[J01CA12, piperacillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Piperacillin.]
[J05AE01, saquinavir, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Medroxyprogesterone acetate may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Medroxyprogesterone acetate.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J01CA02, pivampicillin, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Pivampicillin.]
[J05AG02, delavirdine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Medroxyprogesterone acetate.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Abciximab.]
[D05AX05, tazarotene, The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tazarotene.]
[S01XA13, alteplase, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Alteplase.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Medroxyprogesterone acetate.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Medroxyprogesterone acetate.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Medroxyprogesterone acetate.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Medroxyprogesterone acetate.]
[B05XA01, potassium chloride, Medroxyprogesterone acetate may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Medroxyprogesterone acetate.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Medroxyprogesterone acetate.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Medroxyprogesterone acetate.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Medroxyprogesterone acetate.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Medroxyprogesterone acetate can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Medroxyprogesterone acetate can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Medroxyprogesterone acetate can be increased when combined with Probenecid.]
[C01BA02, procainamide, Medroxyprogesterone acetate may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Procaine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Medroxyprogesterone acetate.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Medroxyprogesterone acetate.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Medroxyprogesterone acetate.]
[R06AD02, promethazine, Medroxyprogesterone acetate may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Medroxyprogesterone acetate may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Medroxyprogesterone acetate.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Medroxyprogesterone acetate.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[N02CC04, rizatriptan, Medroxyprogesterone acetate may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Medroxyprogesterone acetate.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Medroxyprogesterone acetate.]
[N07XX07, dalfampridine, Medroxyprogesterone acetate may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Medroxyprogesterone acetate may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Medroxyprogesterone acetate.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Medroxyprogesterone acetate.]
[A02BA02, ranitidine, Medroxyprogesterone acetate may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[J05AP01, ribavirin, Medroxyprogesterone acetate may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Medroxyprogesterone acetate can be increased when combined with Rifampicin.]
[J01AA09, rolitetracycline, The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Rolitetracycline.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Medroxyprogesterone acetate.]
[N05CA06, secobarbital, The metabolism of Medroxyprogesterone acetate can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The bioavailability of Selegiline can be increased when combined with Medroxyprogesterone acetate.]
[J01GB08, sisomicin, Medroxyprogesterone acetate may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Medroxyprogesterone acetate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Medroxyprogesterone acetate may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Medroxyprogesterone acetate.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.]
